Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

C4 Therapeutics, Inc

CCCC ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.24

▲ +3.92%

Market Cap $521.63M · Vol 983.36K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$521.63M

Small Cap

Div Yield

N/A

EPS Growth

+29.74%

YoY

RSI (14)

73.72

Momentum

Beta

2.97

vs Market

52W High

$5.17

17.91% below

52W Low

$1.70

150.15% above

Volume

983.36K

Avg 792.60K

P/B

0.72

Price-to-book

ROE

-44.44%

Return on equity

Free Float

96.49%

Public shares

Shariah Compliance8 STANDARDS

✗ C4 Therapeutics, Inc (CCCC) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CCCC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.67%

+11.29%

+16.80%

+124.34%

YTD

+121.99%

+80.43%

+25.44%

-89.22%

Financials & Valuation

TTM · Annual

Total Revenue	$35.95M
Net Income	$-104,994,000.00
Revenue Growth (YoY)	+2.75%
Gross Margin	100.00%
Operating Margin	-290.68%
Net Profit Margin	-292.08%
ROE	-44.44%
ROA · ROIC	-29.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4.40
P/B	0.72
P/FCF	N/A
EPS Growth	+29.74%
Outstanding Shares	123.03M

Technical Indicators

50-Day SMA	$3.90
200-Day SMA	$2.93
RSI (14)	73.72
Beta	2.97
52-Week High	$5.17
52-Week Low	$1.70

Volume Today	983.36K
Avg Daily Volume (30D)	792.60K
Relative Volume	1.24x
Volatility (10D)	40.79
Volatility (30D)	61.13
Free Float	96.49%

Analyst Consensus

BUY

Current Price $4.24

Mean Target $13.33

52W Low$1.70 52W High$5.17

Current

Target

$1.70 $5.17

Current Analyst target

+214.47% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00BV2Y9C6

ISINUS12529R1077

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).